We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Medical sector has slightly outperformed the S&P 500 in 2022, down 18%.
A widely-popular company in the realm, AstraZeneca PLC (AZN - Free Report) , is slated to unveil quarterly earnings on November 10th, before market open.
AstraZeneca is one of the largest biopharmaceutical companies in the world. Its business can be broken down into separate lines based on therapeutic classes, including cardiovascular, respiratory, immunology, oncology, rare diseases, and others.
As it stands, the company carries a Zacks Rank #3 (Hold) paired with an overall VGM Score of a B.
How does everything else stack up heading into the release? Let’s find out.
Share Performance & Valuation
AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and visibly outperforming the general market.
Image Source: Zacks Investment Research
Over the last three months, shares have continued on their market-beating trajectory, declining roughly 7% vs. the S&P 500’s decline of more than 9%.
Image Source: Zacks Investment Research
Shares trade at an 18.5X forward earnings multiple, nicely beneath the 22.3X five-year median and reflecting a 27% discount relative to its Zacks Medical sector.
The company sports a Style Score of a B.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bullish regarding their earnings outlook, with four positive earnings estimate revisions hitting the tape over the last several months. The Zacks Consensus EPS Estimate of $0.77 indicates an improvement of more than 40% Y/Y.
Image Source: Zacks Investment Research
AstraZeneca’s top-line also appears to be in good health; the Zacks Consensus Sales Estimate of $11 billion suggests an uptick of more than 11% from year-ago quarterly sales of $9.9 billion.
Quarterly Performance
AZN has been on a strong earnings streak, exceeding revenue and earnings estimates in each of its last three quarters.
Just in its latest print, the company penciled in a sizable 10.3% EPS beat paired with a 3.2% sales surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Putting Everything Together
AZN shares have outperformed the general market across several timeframes in 2022, indicating that buyers have stepped up.
The company’s forward earnings multiple is well below its five-year median and Zacks Medical sector average.
Analysts have been bullish over the last several months, with estimates indicating Y/Y upticks in both revenue and earnings.
The company has consistently exceeded quarterly estimates, exceeding both revenue and EPS expectations in each of its last three releases.
Heading into the print, AstraZeneca PLC (AZN - Free Report) carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 2.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca Q3 Preview: Can Shares Stay Strong?
The Zacks Medical sector has slightly outperformed the S&P 500 in 2022, down 18%.
A widely-popular company in the realm, AstraZeneca PLC (AZN - Free Report) , is slated to unveil quarterly earnings on November 10th, before market open.
AstraZeneca is one of the largest biopharmaceutical companies in the world. Its business can be broken down into separate lines based on therapeutic classes, including cardiovascular, respiratory, immunology, oncology, rare diseases, and others.
As it stands, the company carries a Zacks Rank #3 (Hold) paired with an overall VGM Score of a B.
How does everything else stack up heading into the release? Let’s find out.
Share Performance & Valuation
AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and visibly outperforming the general market.
Image Source: Zacks Investment Research
Over the last three months, shares have continued on their market-beating trajectory, declining roughly 7% vs. the S&P 500’s decline of more than 9%.
Image Source: Zacks Investment Research
Shares trade at an 18.5X forward earnings multiple, nicely beneath the 22.3X five-year median and reflecting a 27% discount relative to its Zacks Medical sector.
The company sports a Style Score of a B.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bullish regarding their earnings outlook, with four positive earnings estimate revisions hitting the tape over the last several months. The Zacks Consensus EPS Estimate of $0.77 indicates an improvement of more than 40% Y/Y.
Image Source: Zacks Investment Research
AstraZeneca’s top-line also appears to be in good health; the Zacks Consensus Sales Estimate of $11 billion suggests an uptick of more than 11% from year-ago quarterly sales of $9.9 billion.
Quarterly Performance
AZN has been on a strong earnings streak, exceeding revenue and earnings estimates in each of its last three quarters.
Just in its latest print, the company penciled in a sizable 10.3% EPS beat paired with a 3.2% sales surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Putting Everything Together
AZN shares have outperformed the general market across several timeframes in 2022, indicating that buyers have stepped up.
The company’s forward earnings multiple is well below its five-year median and Zacks Medical sector average.
Analysts have been bullish over the last several months, with estimates indicating Y/Y upticks in both revenue and earnings.
The company has consistently exceeded quarterly estimates, exceeding both revenue and EPS expectations in each of its last three releases.
Heading into the print, AstraZeneca PLC (AZN - Free Report) carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 2.1%.